Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Nov 16, 2014; 2(11): 717-723
Published online Nov 16, 2014. doi: 10.12998/wjcc.v2.i11.717
Published online Nov 16, 2014. doi: 10.12998/wjcc.v2.i11.717
Bevacizumab maintenance in metastatic colorectal cancer: How long?
Alfonso De Stefano, Roberto Moretto, Chiara Alessandra Cella, Francesco Jacopo Romano, Lucia Raimondo, Giovanni Fiore, Francesca Di Pietro, Sabino De Placido, Chiara Carlomagno, Department of Clinical Medicine and Surgery, School of Medicine, University of Naples “Federico II”, 80131 Napoli, Italy
Stefano Pepe, Department of Medicine, School of Medicine and Pharmacology, University of Salerno, 84081 Baronissi (SA), Italy
Author contributions: De Stefano A drafted the manuscript, collected the figures, and approved the final version of the manuscript; Moretto R, Cella CA, Romano FJ, Raimondo L, Fiore G, Di Pietro F, Pepe S, De Placido S revised the manuscript and approved the final version of the manuscript; Carlomagno C worked on data interpretation, revised the manuscript, and approved the final version of the manuscript.
Correspondence to: Alfonso De Stefano, MD, PhD, Department of Clinical Medicine and Surgery, University of Naples “Federico II”, Via Sergio Pansini, 5, 80131 Napoli, Italy. alfonso.destefano@unina.it
Telephone: +39-08-17464984 Fax: +39-08-12203147
Received: April 2, 2014
Revised: July 30, 2014
Accepted: September 6, 2014
Published online: November 16, 2014
Processing time: 221 Days and 18 Hours
Revised: July 30, 2014
Accepted: September 6, 2014
Published online: November 16, 2014
Processing time: 221 Days and 18 Hours
Core Tip
Core tip: A colorectal cancer patient with lung metastases received bevacizumab combined with chemotherapy for six months, and then bevacizumab monotherapy as maintenance treatment for more than three years. The patient achieved a complete response without evidence of side effects. He remains relapse free 58 mo after diagnosis.